← back to search

Mark Rosen

Amgen (United States) · US
Area of research
Radiology, Nuclear Medicine and Imaging · Pulmonary and Respiratory Medicine
Research interest
Research interests include MRI in cancer diagnosis, Radiomics and Machine Learning in Medical Imaging, Medical Imaging Techniques and Applications, and Advanced MRI Techniques and Applications.
h-index
54
citations
11,291
works
323
NIH funding
primary concept
Medicine
email

Recent publications

The QIBA Profile for Dynamic Susceptibility Contrast MRI Quantitative Imaging Biomarkers for Assessing Gliomas
Radiology 2024cited by 8position: middledoi
Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement
European Urology 2023cited by 39position: middledoi
Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology
Journal of Clinical Oncology 2023cited by 27position: middledoi
Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals
Cell 2022cited by 174position: middledoi
Breast MRI during Neoadjuvant Chemotherapy: Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response
Radiology 2021cited by 36position: middledoi
Dextran-Coated Cerium Oxide Nanoparticles: A Computed Tomography Contrast Agent for Imaging the Gastrointestinal Tract and Inflammatory Bowel Disease
ACS Nano 2020cited by 173position: middledoi
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL
npj Breast Cancer 2020cited by 81position: middledoi
Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE‐MRI derived biomarkers in multicenter oncology trials
Journal of Magnetic Resonance Imaging 2019cited by 49position: middledoi
Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer
Clinical Cancer Research 2019cited by 47position: middledoi
Comparing radiomic classifiers and classifier ensembles for detection of peripheral zone prostate tumors on T2-weighted MRI: a multi-site study
BMC Medical Imaging 2019cited by 44position: middledoi
Multisite evaluation of radiomic feature reproducibility and discriminability for identifying peripheral zone prostate tumors on MRI
Journal of Medical Imaging 2019cited by 39position: middledoi
Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE‐MRI derived biomarkers in multicenter oncology trials
Journal of Magnetic Resonance Imaging 2018cited by 398position: middledoi
Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial
Radiology 2018cited by 281position: middledoi
MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial
American Journal of Roentgenology 2018cited by 128position: middledoi
Test–retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial
Journal of Magnetic Resonance Imaging 2018cited by 108position: middledoi
Empirical evaluation of cross-site reproducibility in radiomic features for characterizing prostate MRI
Medical Imaging 2018: Computer-Aided Diagnosis 2018cited by 25position: lastdoi
MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial
Journal of Magnetic Resonance Imaging 2016cited by 53position: middledoi
Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival—Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL
Radiology 2015cited by 275position: middledoi
Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
Annals of Surgical Oncology 2013cited by 111position: middledoi
Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL
Radiology 2012cited by 486position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Laura J. Esserman · UCSF Helen Diller Family Comprehensive Cancer Center7 papers (2012–2018)Nola M. Hylton · UCSF Helen Diller Family Comprehensive Cancer Center6 papers (2012–2018)Savannah C. Partridge · University of Washington5 papers (2015–2018)Helga S. Marques · Brown University5 papers (2012–2018)David C. Newitt · University of California, San Francisco4 papers (2015–2018)Thomas L. Chenevert · University of Michigan–Ann Arbor4 papers (2018–2019)Paul T. Weatherall · Southwestern Medical Center4 papers (2012–2018)Elizabeth A. Morris · University of Surrey4 papers (2012–2018)Sandra M. Polin · Georgetown University4 papers (2012–2018)Etta D. Pisano · Georgetown University4 papers (2012–2018)Mitchell D. Schnall · ECOG-ACRIN Cancer Research Group4 papers (2012–2018)Constance D. Lehman · Breast Center4 papers (2012–2018)Gillian M. Newstead · University of Chicago4 papers (2012–2018)Wanda K. Bernreuter · University of Alabama at Birmingham3 papers (2012–2018)Satish E. Viswanath · Case Western Reserve University3 papers (2018–2019)Anant Madabhushi · Emory University3 papers (2018–2019)Prathyush Chirra · Case Western Reserve University3 papers (2018–2019)Patrick J. Bolan · Stanford University3 papers (2016–2018) · 3 papers (2018–2019)Andrei S. Purysko · Cleveland Clinic3 papers (2018–2019)